Tandem Diabetes Care, Inc.

NASDAQ (USD): Tandem Diabetes Care, Inc. (TNDM)

Last Price

41.78

Today's Change

+1.32 (3.26%)

Day's Change

39.64 - 41.88

Trading Volume

869,432

Profile
TNDM

Exchange:  NASDAQ Global Market NASDAQ Global Market

Currency:  USD USD

Sector:  Healthcare - Healthcare Healthcare - Healthcare

Industry: 

CEO:  Mr. John F. Sheridan Mr. John F. Sheridan

Full Time Employees:  2,400 2,400

IPO Date:  2013-11-14 2013-11-14

CIK:  0001438133 0001438133

ISIN:  US8753722037 US8753722037

CUSIP:  875372203 875372203

Beta:  1.33 1.33

Last Dividend:  0.00 0.00

Dcf Diff:  41.77 41.77

Dcf:  -0.44 -0.44

Description

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

Address

11075 Roselle Street,
San Diego, CA 92121, US

858 366 6900

http://www.tandemdiabetes.com

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment